Advice
Following a full submission
Carmustine implant (Gliadel®) is accepted for use within NHS Scotland for the treatment of newly diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation.
In the pivotal study, the use of carmustine implants was associated with a 29% relative decrease in the risk of death, which equates to an increase in median survival time of 2.3 months.
Download detailed advice114KB (PDF)
Medicine details
- Medicine name:
- Carmustine implant (Gliadel®)
- SMC ID:
- 215/05
- Indication:
- Newly diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation
- Pharmaceutical company
- Link Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 December 2005